DK3515455T3 - Forbindelser til behandling af lidelser i lipoproteinmetabolismen - Google Patents
Forbindelser til behandling af lidelser i lipoproteinmetabolismen Download PDFInfo
- Publication number
- DK3515455T3 DK3515455T3 DK17776978.3T DK17776978T DK3515455T3 DK 3515455 T3 DK3515455 T3 DK 3515455T3 DK 17776978 T DK17776978 T DK 17776978T DK 3515455 T3 DK3515455 T3 DK 3515455T3
- Authority
- DK
- Denmark
- Prior art keywords
- disorders
- compounds
- treatment
- lipoprotein metabolism
- lipoprotein
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 230000008604 lipoprotein metabolism Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
- A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Botany (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201670733 | 2016-09-20 | ||
| PCT/EP2017/073747 WO2018054959A1 (en) | 2016-09-20 | 2017-09-20 | Compounds for treatment of lipoprotein metabolism disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3515455T3 true DK3515455T3 (da) | 2021-07-05 |
Family
ID=59974406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17776978.3T DK3515455T3 (da) | 2016-09-20 | 2017-09-20 | Forbindelser til behandling af lidelser i lipoproteinmetabolismen |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11173177B2 (enExample) |
| EP (1) | EP3515455B1 (enExample) |
| JP (1) | JP7046381B2 (enExample) |
| CN (1) | CN110494145A (enExample) |
| AU (1) | AU2017329799A1 (enExample) |
| CA (1) | CA3035875A1 (enExample) |
| DK (1) | DK3515455T3 (enExample) |
| ES (1) | ES2871783T3 (enExample) |
| WO (1) | WO2018054959A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016235662B2 (en) * | 2015-03-20 | 2020-07-30 | Aarhus Universitet | Inhibitors of PCSK9 for treatment of lipoprotein metabolism disorders |
| KR102137147B1 (ko) * | 2018-07-16 | 2020-07-24 | 경희대학교 산학협력단 | 벤질 알파-d-갈락토피라노사이드 또는 (-)-세코이소라리시레시놀-9'-o-베타-d-글루코피라노사이드를 포함하는 당뇨병 예방 또는 치료용 조성물 |
| SE543275C2 (en) * | 2019-03-07 | 2020-11-10 | Tx Medic Ab | Treatment efficiency evaluation |
| WO2021122793A1 (en) * | 2019-12-17 | 2021-06-24 | Norinvent Ab | Sulfated disaccharides as enhancers of transmucosal drug uptake |
| WO2022046873A1 (en) * | 2020-08-25 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Treatment of sepsis with pcsk9 and ldlr modulators |
| CN116854752A (zh) * | 2022-03-28 | 2023-10-10 | 南开大学 | 肝素三糖结构化合物及其制药应用 |
| CN116270507A (zh) * | 2023-03-02 | 2023-06-23 | 青岛海洋生物医药研究院股份有限公司 | 一种含脂蛋白脂酶刺激剂的舌下含片及其制备方法和应用 |
| CN119708089A (zh) * | 2023-09-27 | 2025-03-28 | 南开大学 | 一种磺酸化三糖及其制备方法和治疗应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4602003A (en) * | 1982-05-17 | 1986-07-22 | Medical Research Foundation Of Oregon | Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia |
| AU2753292A (en) * | 1991-10-04 | 1993-05-03 | Procter & Gamble Company, The | Cholesterol lowering compounds and process for making them |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5366473A (en) | 1992-08-18 | 1994-11-22 | Ultrasonic Sensing And Monitoring Systems, Inc. | Method and apparatus for applying vascular grafts |
| GB9221657D0 (en) | 1992-10-15 | 1992-11-25 | Scotgen Ltd | Recombinant bispecific antibodies |
| CA2117477C (en) | 1992-12-11 | 2001-06-12 | Peter S. Mezes | Multivalent single chain antibodies |
| MXPA03004793A (es) | 2000-11-30 | 2004-12-03 | Medarex Inc | Roedores transgenicos transcromosomales para elaborar anticuerpos humnanos. |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| CA2704201C (en) * | 2007-10-16 | 2015-06-30 | Progen Pharmaceuticals Limited | Novel sulfated oligosaccharide derivatives |
| TWI445716B (zh) | 2008-09-12 | 2014-07-21 | Rinat Neuroscience Corp | Ｐｃｓｋ９拮抗劑類 |
| JP5701308B2 (ja) | 2009-10-29 | 2015-04-15 | インダストリー−アカデミック コーポレーション ファウンデーション，ヨンセイ ユニバーシティ | 新規血管漏出遮断剤 |
| EP2794661B1 (en) | 2011-12-20 | 2019-03-06 | Adaerata, Limited Partnership | Single domain antibodies as inhibitors of pcsk9 |
| WO2013148284A1 (en) | 2012-03-29 | 2013-10-03 | Genentech, Inc. | Antibodies that bind to a pcsk9 cleavage site and methods of use |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| EP3210972A1 (en) | 2012-05-25 | 2017-08-30 | Catabasis Pharmaceuticals, Inc. | Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9) |
| CA2877766A1 (en) | 2012-07-03 | 2014-01-09 | Majambu Mbikay | Quercetin-3-glucoside and uses thereof |
| JP2015529655A (ja) * | 2012-08-02 | 2015-10-08 | ステルス ペプチドズ インターナショナル インコーポレイテッド | アテローム性硬化症の処置方法 |
| CA2906508A1 (en) | 2013-03-15 | 2014-09-25 | Amgen, Inc. | Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 |
| EP3197492A1 (en) * | 2014-09-23 | 2017-08-02 | Pfizer Inc | Treatment with anti-pcsk9 antibodies |
| AU2016235662B2 (en) | 2015-03-20 | 2020-07-30 | Aarhus Universitet | Inhibitors of PCSK9 for treatment of lipoprotein metabolism disorders |
-
2017
- 2017-09-20 ES ES17776978T patent/ES2871783T3/es active Active
- 2017-09-20 WO PCT/EP2017/073747 patent/WO2018054959A1/en not_active Ceased
- 2017-09-20 US US16/334,131 patent/US11173177B2/en not_active Expired - Fee Related
- 2017-09-20 AU AU2017329799A patent/AU2017329799A1/en not_active Abandoned
- 2017-09-20 EP EP17776978.3A patent/EP3515455B1/en active Active
- 2017-09-20 CA CA3035875A patent/CA3035875A1/en not_active Abandoned
- 2017-09-20 JP JP2019513787A patent/JP7046381B2/ja not_active Expired - Fee Related
- 2017-09-20 CN CN201780069925.3A patent/CN110494145A/zh active Pending
- 2017-09-20 DK DK17776978.3T patent/DK3515455T3/da active
-
2021
- 2021-08-16 US US17/403,102 patent/US20220054530A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017329799A1 (en) | 2019-04-11 |
| WO2018054959A1 (en) | 2018-03-29 |
| ES2871783T3 (es) | 2021-11-02 |
| JP2019529402A (ja) | 2019-10-17 |
| US20190275074A1 (en) | 2019-09-12 |
| JP7046381B2 (ja) | 2022-04-04 |
| US20220054530A1 (en) | 2022-02-24 |
| US11173177B2 (en) | 2021-11-16 |
| EP3515455A1 (en) | 2019-07-31 |
| CN110494145A (zh) | 2019-11-22 |
| CA3035875A1 (en) | 2018-03-29 |
| EP3515455B1 (en) | 2021-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3307262T3 (da) | Forbindelser til anvendelse ved behandling af neuromuskulære lidelser | |
| DK3743070T3 (da) | Forbindelser til behandling af kinaseafhængige lidelser | |
| DK3570844T3 (da) | Azolopyrimidin til behandlingen af kræftrelaterede lidelser | |
| DK3261640T3 (da) | 5ht-agonister til behandling af epilepsilidelser | |
| DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
| IL247452A0 (en) | Compounds for treatment of complement mediated disorders | |
| DK3125875T3 (da) | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande | |
| DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
| DK3515455T3 (da) | Forbindelser til behandling af lidelser i lipoproteinmetabolismen | |
| DK3143025T3 (da) | Forbindelser til behandling af spinal muskelatrofi | |
| DK3433266T3 (da) | Fremgangsmåder til behandling af mitokondrieforstyrrelser | |
| DK3102213T3 (da) | Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3485890T3 (da) | Sglt2-hæmmere til behandling af stofskifteforstyrrelser hos hundedyr | |
| DK3524255T3 (da) | Sammensætning til behandling af acne | |
| DK3503890T3 (da) | Anvendelse af pridopidin til behandling af dystonier | |
| DK3288577T3 (da) | Adiponectin-peptidomimetika til behandling af øjenlidelser | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| DK3328864T3 (da) | Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser | |
| DK3324824T3 (da) | Fremgangsmåde til behandling af binokulare dysfunktioner | |
| DK3380471T3 (da) | Tetrahydro-8h-pyrido[1,2-a]pyrazin-8-oner som comt-inhibitorer til behandlingen af neurodegenerative lidelser | |
| DK3256466T3 (da) | 1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser | |
| DK3192524T3 (da) | Hgf præparat egnet til behandling af neurologiske lidelser | |
| DK3430143T3 (da) | Inhibitorer af SRSF1 til behandlingen af neurodegenerative sygdomme | |
| DK3724173T3 (da) | Forbindelser til behandling af neuromuskulære lidelser |